Paul G. Kemps

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Histiocytosis development and clinical variation through the lens of genomics.

Histiocytosis development and clinical variation through the lens of genomics.

Journal: The Journal of pathology

Published: February 19, 2026

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Journal: Blood cancer journal

Published: December 15, 2025

ALKATI Drives Nuclear Anaplastic Lymphoma Kinase (ALK) Expression in Histiocytic Neoplasms Without ALK Fusions.

ALKATI Drives Nuclear Anaplastic Lymphoma Kinase (ALK) Expression in Histiocytic Neoplasms Without ALK Fusions.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: August 08, 2025

Advancing sarcoma diagnostics with expanded DNA methylation-based classification.

Advancing sarcoma diagnostics with expanded DNA methylation-based classification.

Journal: medRxiv : the preprint server for health sciences

Published: July 09, 2025

NTRK1-rearranged histiocytosis: clinicopathologic and molecular features.

NTRK1-rearranged histiocytosis: clinicopathologic and molecular features.

Journal: Blood advances

Published: February 10, 2025

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms.

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms.

Journal: Blood neoplasia

Published: September 03, 2024

Predisposition Footprints in the Somatic Genome of Wilms Tumors.

Predisposition Footprints in the Somatic Genome of Wilms Tumors.

Journal: Cancer discovery

Published: June 20, 2024

Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.

Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.

Journal: Clinical immunology (Orlando, Fla.)

Published: May 22, 2024

Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.

Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.

Journal: Blood advances

Published: May 20, 2024

Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue.

Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue.

Journal: Blood

Published: May 14, 2024

ALK-Positive Histiocytosis-A Distinct Histiocytic Entity Deserving Recognition.

ALK-Positive Histiocytosis-A Distinct Histiocytic Entity Deserving Recognition.

Journal: JAMA dermatology

Published: April 24, 2024

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Journal: Blood neoplasia

Published: April 11, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026